Alli hits European stores
This article was originally published in The Tan Sheet
Executive Summary
Pharmacies across Europe now sell GlaxoSmithKline's non-prescription weight-loss drug alli (orlistat 60 mg), the firm says April 20. The European Commission, in its first centralized Rx-to-OTC switch process, approved the product for non-Rx sale to adults with a body mass index of 28 kg/m2 or more in all 27 EU member countries (1"The Tan Sheet" Jan. 26, 2009, In Brief)
You may also be interested in...
GSK's Launches, Global Expansion Drive Consumer Sales Ahead Of Market
Brand innovation, continued investment in marketing and global expansion help drive up GlaxoSmithKline's consumer health care sales significantly faster than overall market growth, the firm says
Alli first centralized switch
The European Union approves GlaxoSmithKline's weight-loss drug alli (orlistat 60 mg) for nonprescription sale in all 27 member states and Norway. The company says Jan. 21 it plans to launch alli - the first centralized EU switch - in the coming months. While all EU members agree to sell alli as nonprescription, each country chooses whether to make it available over the counter or behind the counter, the European Medicines Agency says (1"The Tan Sheet" Nov. 17, 2008, p. 6)
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.